|
|
|
CytRx Corporation
CytRx Corporation (NASDAQ: CYTR), is a biopharmaceutical company engaged in the development of high-value therapeutics based on its small molecule chaperone amplification technology.
About CytRx Corp >
News & Events >
Investor Relations >
Careers >
Contact Us > | | Platform Technologies
CytRx is developing products based on small molecule chaperone amplification technology in a variety of therapeutic indications including ALS, stroke recovery and diabetic wound healing. In addition, CytRx owns approximately 49% of RXi Pharmaceuticals Corporation (NASD: RXII), a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases.
About Platform Technologies >
Chaperone Amplification >
RXi Pharmaceuticals Corporation > |
|
News & Events
06/18/08 - CytRx Corporation to Present at the Jefferies 2nd Annual Healthcare Conference More
06/09/08 - CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc. More
06/03/08 - CytRx to Present at the GTCbio's Third Assay Development & Screening Technologies Conference More
06/02/08 - CytRx to Present Favorable Study Data with Iroxanadine in Diabetic Wound Healing at the Third Congress of the World Union of Wound Healing Societies More
See more press releases > |  Webcasts
6/26/08 - Jefferies 2nd Annual Healthcare Conference,11:15 a.m. EDT More | 
|
|
| |
| |
|
